Skip to content Skip to footer
Subscribe Now
Viewpoints_Dr. Trevor Feinstein and Dr. Lan Huang
VIEWPOINTS

PharmaShots Interview: Dr. Trevor Feinstein and BeyondSpring’s Dr. Lan Huang Shares Insight on the Data of Plinabulin + Docetaxel for NSCLC with EGFR Wild Type

In an interview with PharmaShots, Dr. Trevor Feinstein (Hematology Specialist in Fayetteville, GA) and Dr. Lan Huang (Co-founder, Chairman, and CEO at BeyondSpring) shared their views on the data of Plinabulin + Docetaxel in P-III DUBLIN-3 trial for NSCLC with EGFR Wild Type Shots: The P-III DUBLIN-3 trial evaluates plinabulin + docetaxel vs docetaxel alone in 599 patients with 2L & 3L NSCLC EGFR wild type,…
November 8, 2021

Read more

Viewpoints_Dr. Bob Cobuzzi
VIEWPOINTS

PharmaShots Interview: Diffusion’s Dr. Bob Cobuzzi Shares Insights on the Trans Sodium Crocetinate (TSC) to Improve Hypoxia

In an interview with PharmaShots, Dr. Bob Cobuzzi, CEO, President, and Board Member at Diffusion shared his views on the trans sodium crocetinate (TSC) to improve patient outcomes & paradigm of oxygen deprivation treatment Shots: Diffusion's TSC directly targets and relieves oxygen-deprivation in affected tissue by enhancing oxygen diffusion & was designed to treat hypoxia include trauma, heart attack, stroke,…
November 3, 2021

Read more

Viewpoints_Brady Granier
VIEWPOINTS

PharmaShots Interview: BioCorRx’ Brady Granier Shares Insights on the New Agreement with Recro to Support BICX104

In an interview with PharmaShots, Brady Granier, CEO, President, and Director at BioCorRx shared his views on the companies existing collaboration & expands with the signing of a new development and manufacturing agreement to support BICX104 for opioid use disorder Shots: The companies have expanded an ongoing collaboration by signing a new development and manufacturing agreement to support BICX104 for…
November 2, 2021

Read more

Exclusive_Dr. Briggs W. Morrison_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Dr. Briggs W. Morrison of Syndax Share Insight on the Syndax’ Agreement with Incyte for Axatilimab

In an interview with PharmaShots, Dr. Briggs W. Morrison, MD, Chief Executive Officer and Director at Syndax share his views on the license agreement for axatilimab with Incyte to treat cGVHD and other fibrotic diseases Shots: The companies collaborated to develop and commercialize Syndax's axatilimab (anti-CSF-1R mAb) & will get a 50:50 US profit share Incyte will lead the…
November 1, 2021

Read more

Viewpoints_Txema Sanz
VIEWPOINTS

PharmaShots Interview: Astellas’ Txema Sanz Shares Insights on the Evrenzo (roxadustat) for Symptomatic Anemia Associated with Chronic Kidney Disease

In an interview with PharmaShots, Txema Sanz, Senior Vice President and Head of the Global Medical Specialties at Astellas shared his views on the EC's approval of Evrenzo (roxadustat) for the Treatment of symptomatic anemia associated with Chronic Kidney Disease Shots: The approval is based on the P-III program including 8 studies evaluating Evrenzo in 9600 patients with symptomatic anemia associated with…
October 27, 2021

Read more

Exclusive_Jonathan Benjamin_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Jonathan Benjamin of Atreca Share Insight on the Data of ATRC-101 to Treat Solid Tumor

In an interview with PharmaShots, Jonathan Benjamin, MD, Ph.D., Senior Vice President & Clinical Research of Atreca shared his views on the initial data from the dose-escalation portion of its ongoing P-Ib trial for ATRC-101 to treat solid tumor Shots: The ongoing P-Ib trial evaluates ATRC-101 in patients with solid tumors & 26 patients had been dosed in a trial as of data cut-off…
October 22, 2021

Read more

Viewpoints_Rich Birhanzel
VIEWPOINTS

PharmaShots Interview: Accenture’s Rich Birhanzel Shares Insight on the Investment in ixlayer

In an interview with PharmaShots, Rich Birhanzel, Senior Managing Director & Global Health Lead at Accenture shared his views on the investment in ixlayer to provide health solutions for diagnostic testing Shots: The company has made a strategic investment in ixlayer through Accenture Ventures to expand access to virtual diagnostic health testing. The company's telehealth platform allows players across the healthcare ecosystem…
October 22, 2021

Read more

Viewpoints_Anish Suri
VIEWPOINTS

PharmaShots Interview: Cue Biopharma’s Anish Suri Shares Insights on the Data of CUE-401 Presented at 2021 FOCIS Annual Meeting

In an interview with PharmaShots, Anish Suri, Ph.D., President, and Chief Scientific Officer at Cue Biopharma shared his views on new preclinical data of CUE-401 for the treatment of autoimmune diseases at the 2021 FOCIS Annual Meeting Shots: The company has reported the preclinical data of CUE-401 which can induce & expand regulatory T cells in vitro and in vivo & has the potential to…
October 15, 2021

Read more

Viewpoints_Brandon Smith
VIEWPOINTS

PharmaShots Interview: Prothena’s Brandon Smith Shares Insight on the Acquisition of Prothena and Novo Nordisk

In an interview with PharmaShots, Brandon Smith, Chief Business Officer at Prothena shared his views on Novo Nordisk's acquisition of Prothena's ATTR amyloidosis program includes PRX004 Shots: The companies have entered into a definitive purchase agreement in which Novo Nordisk has acquired Prothena's PRX004 and broader ATTR amyloidosis program Novo Nordisk acquires Prothena's subsidiary and gets WW rights to the IP and…
October 15, 2021

Read more

Load more